Literature DB >> 1670603

Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype.

A M Arvin1, M Sharp, S Smith, C M Koropchak, P S Diaz, P Kinchington, W Ruyechan, J Hay.   

Abstract

Immunity to varicella-zoster virus (VZV), a member of the alpha-herpes virus family, exemplifies the host response to an ubiquitous human viral pathogen. In this investigation of the cytotoxic T lymphocyte (CTL) response to VZV, the depletion of CD4+ T lymphocytes made it possible to demonstrate CD8(+)-mediated cytotoxic function against autologous VZV-infected lymphoblastoid cells targets. CTL recognition of two major VZV proteins, the immediate early protein (IE62) and gp I, was demonstrated in limiting dilution cultures of T lymphocytes obtained from immune donors, stimulated with inactivated VZV Ag, and tested against lymphoblastoid cells infected with vaccinia recombinants expressing these VZV proteins. Among 11 VZV donors tested at least 20 y after primary infection, the mean precursor frequency for T lymphocytes that recognized the IE62 protein was 1:105,000 +/- 85,000 SD, with a range of 1:13,000 to 1:231,000. The mean frequency of CTL precursors specific for gp I in 11 subjects was equivalent, with a mean of 1:121,000 +/- 86,000 SD (range 1:15,000 to 1:228,000) (p = 0.68). Limiting dilution cultures were also prepared using purified CD4+ or CD8+ T lymphocyte populations recovered from PBMC by sterile fluorescence-activated cell sorting. CTL precursors that recognized the IE62 protein or gp I were derived from each of the major T lymphocyte populations by stimulation with inactivated VZV Ag; CD4+ and CD8+ CTL precursor frequencies for the IE62 protein and gp I were equivalent (p = 0.2). We conclude that antiviral CTL activity against targets expressing VZV proteins was mediated equally well by T lymphocytes of the CD4+ or CD8+ phenotype and that antiviral CTL function could be elicited in each subpopulation by exposure to non-infectious viral Ag.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1670603

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

Review 1.  Contributions of humoral and cellular immunity to vaccine-induced protection in humans.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Virology       Date:  2011-01-08       Impact factor: 3.616

Review 2.  Herpesvirus interference with major histocompatibility complex class II-restricted T-cell activation.

Authors:  Emmanuel J Wiertz; Robert Devlin; Helen L Collins; Maaike E Ressing
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

3.  Kaposi's sarcoma-associated herpesvirus inhibits expression and function of endothelial cell major histocompatibility complex class II via suppressor of cytokine signaling 3.

Authors:  L M Butler; H C Jeffery; R L Wheat; H M Long; P C Rae; G B Nash; D J Blackbourn
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

4.  Varicella-zoster virus glycoproteins B and E are major targets of CD4+ and CD8+ T cells reconstituting during zoster after allogeneic transplantation.

Authors:  Patrick Kleemann; Eva Distler; Eva M Wagner; Simone Thomas; Sebastian Klobuch; Steffi Aue; Elke Schnürer; Hansjörg Schild; Matthias Theobald; Bodo Plachter; Stefan Tenzer; Ralf G Meyer; Wolfgang Herr
Journal:  Haematologica       Date:  2011-12-29       Impact factor: 9.941

5.  IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp).

Authors:  G Ferrari; K King; K Rathbun; C A Place; M V Packard; J A Bartlett; D P Bolognesi; K J Weinhold
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

6.  Attenuation of the adaptive immune response in rhesus macaques infected with simian varicella virus lacking open reading frame 61.

Authors:  Christine Meyer; Amelia Kerns; Kristen Haberthur; Jesse Dewane; Joshua Walker; Wayne Gray; Ilhem Messaoudi
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

7.  Immunization with the immediate-early tegument protein (open reading frame 62) of varicella-zoster virus protects guinea pigs against virus challenge.

Authors:  C Sabella; P W Lowry; G M Abbruzzi; C M Koropchak; P R Kinchington; M Sadegh-Zadeh; J Hay; W T Ruyechan; A M Arvin
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

8.  Parainfluenza type 1 virus-infected cells are killed by both CD8+ and CD4+ cytotoxic T cell precursors.

Authors:  K S Slobod; J E Allan
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

9.  Identification of varicella-zoster virus-specific CD8 T cells in patients after T-cell-depleted allogeneic stem cell transplantation.

Authors:  Pim L J van der Heiden; Renate de Boer; Dirk M van der Steen; Michel G D Kester; Menno W A G van der Hoorn; Wilmy M E Haarman; Helen E Barnby-Porritt; Jeremy W Fry; C E Napper; Erik W A Marijt; Roel Willemze; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

10.  Identification of two epitopes on the dengue 4 virus capsid protein recognized by a serotype-specific and a panel of serotype-cross-reactive human CD4+ cytotoxic T-lymphocyte clones.

Authors:  S J Gagnon; W Zeng; I Kurane; F A Ennis
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.